Trisphosphate isomerase 1 (TPI1) is a glycolysis enzyme that is described as a glycolysis-relevant biomarker of pancreatic ductal adenocarcinoma by several researchers; its increase in expression is positively associated with an adverse reaction to chemotherapy (Follia et al., 2019). This evidence concerns the gene TPI1 and pancreatic ductal adenocarcinoma.